Proteomic Analysis of Lung Cancer for Adjuvant Therapy
Author Information
Author(s): Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H
Primary Institution: Tokyo Medical University
Hypothesis
Can proteomic analysis identify biomarkers for predicting response to adjuvant chemotherapy in stage I lung adenocarcinoma?
Conclusion
Patients with no expression of myosin IIA or vimentin have a better prognosis without the need for adjuvant chemotherapy.
Supporting Evidence
- Patients lacking myosin IIA and vimentin expression showed a 100% relapse-free survival rate at 5 years.
- 51 out of 90 patients showed overexpression of myosin IIA.
- 48 out of 90 patients showed overexpression of vimentin.
- Statistically significant differences in survival rates were found between patients with and without expression of myosin IIA and vimentin.
Takeaway
This study looked at proteins in lung cancer to see if they could help doctors know who would benefit from chemotherapy after surgery. It found that some patients do better without chemotherapy.
Methodology
The study used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze protein expression in lung cancer specimens and validated findings with immunohistochemistry.
Potential Biases
Potential bias in patient selection and the retrospective nature of the analysis.
Limitations
The study was limited by the small sample size and the inability to identify clear biomarkers for predicting chemotherapy response.
Participant Demographics
The study included 90 patients with stage I lung adenocarcinoma, with a median age of 65 years, and a gender distribution of 60% male and 40% female.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website